Sven Mensing

1.1k total citations · 1 hit paper
43 papers, 638 citations indexed

About

Sven Mensing is a scholar working on Genetics, Hepatology and Epidemiology. According to data from OpenAlex, Sven Mensing has authored 43 papers receiving a total of 638 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Genetics, 14 papers in Hepatology and 11 papers in Epidemiology. Recurrent topics in Sven Mensing's work include Chronic Lymphocytic Leukemia Research (14 papers), Hepatitis C virus research (14 papers) and HIV/AIDS drug development and treatment (8 papers). Sven Mensing is often cited by papers focused on Chronic Lymphocytic Leukemia Research (14 papers), Hepatitis C virus research (14 papers) and HIV/AIDS drug development and treatment (8 papers). Sven Mensing collaborates with scholars based in United States, Germany and Egypt. Sven Mensing's co-authors include Walid M. Awni, Sven Stodtmann, Rajeev Menon, Ana Victoria Ponce Bobadilla, Rod Humerickhouse, Hao Xiong, Ahmed Hamed Salem, Peter Noertersheuser, Jianning Yang and Sathej Gopalakrishnan and has published in prestigious journals such as Blood, Gastroenterology and Cancer Research.

In The Last Decade

Sven Mensing

40 papers receiving 627 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Practical guide to SHAP analysis: Explaining supervised machine learning model predictions in drug development

2024 115 citations Ana Victoria Ponce Bobadilla, Sven Mensing et al. Clinical and Translational Science profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sven Mensing United States	12	146	137	129	113	112	43	638
Hideaki Fujiwara Japan	17	275 1.9×	214 1.6×	75 0.6×	223 2.0×	190 1.7×	71	909
Nisha Nair United Kingdom	13	112 0.8×	79 0.6×	73 0.6×	61 0.5×	17 0.2×	40	442
Chris S.R Hatton United Kingdom	14	122 0.8×	122 0.9×	189 1.5×	234 2.1×	42 0.4×	21	855
Michael Bernimoulin Switzerland	13	336 2.3×	156 1.1×	31 0.2×	126 1.1×	70 0.6×	17	714
Ian Perry United Kingdom	11	238 1.6×	73 0.5×	18 0.1×	109 1.0×	64 0.6×	27	1.0k
S Peller Israel	16	304 2.1×	168 1.2×	144 1.1×	323 2.9×	38 0.3×	41	780
Veera Baladandayuthapani United States	13	316 2.2×	44 0.3×	73 0.6×	160 1.4×	46 0.4×	28	780
Huiqiang Huang China	16	218 1.5×	55 0.4×	77 0.6×	352 3.1×	72 0.6×	79	819
Pooja Advani United States	17	219 1.5×	156 1.1×	79 0.6×	358 3.2×	43 0.4×	67	799

Countries citing papers authored by Sven Mensing

Since Specialization

Citations

This map shows the geographic impact of Sven Mensing's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sven Mensing with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sven Mensing more than expected).

Fields of papers citing papers by Sven Mensing

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sven Mensing. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sven Mensing. The network helps show where Sven Mensing may publish in the future.

Co-authorship network of co-authors of Sven Mensing

This figure shows the co-authorship network connecting the top 25 collaborators of Sven Mensing. A scholar is included among the top collaborators of Sven Mensing based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sven Mensing. Sven Mensing is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bobadilla, Ana Victoria Ponce, Ali Farnoud, Holger Fröhlich, et al.. (2025). Predictive AI in Clinical Pharmacology: A Call to Action to Develop Robust Benchmarking Practices. CPT Pharmacometrics & Systems Pharmacology. 15(1). e70155–e70155.

Bobadilla, Ana Victoria Ponce, et al.. (2024). Practical guide to SHAP analysis: Explaining supervised machine learning model predictions in drug development. Clinical and Translational Science. 17(11). e70056–e70056. 115 indexed citations breakdown →

Suleiman, Ahmed A., et al.. (2024). Population Pharmacokinetic and Exposure–Response Modeling to Inform Risankizumab Dose Selection in Patients With Ulcerative Colitis. Clinical Pharmacology & Therapeutics. 116(3). 847–857. 5 indexed citations

Goteti, Kosalaram, Mindy Magee, Sven Mensing, et al.. (2023). Opportunities and Challenges of Disease Progression Modeling in Drug Development – An IQ Perspective. Clinical Pharmacology & Therapeutics. 114(2). 266–274. 5 indexed citations

Bobadilla, Ana Victoria Ponce, et al.. (2023). Integrating machine learning with pharmacokinetic models: Benefits of scientific machine learning in adding neural networks components to existing PK models. CPT Pharmacometrics & Systems Pharmacology. 13(1). 41–53. 9 indexed citations

Badawi, Mohamed, Xin Chen, Patrick Marroum, et al.. (2022). Bioavailability Evaluation of Venetoclax Lower-Strength Tablets and Oral Powder Formulations to Establish Interchangeability with the 100 mg Tablet. Clinical Drug Investigation. 42(8). 657–668. 6 indexed citations

Nuthalapati, Silpa, Sven Stodtmann, Stacie Peacock Shepherd, et al.. (2019). Exposure–response analysis to inform the optimal dose of veliparib in combination with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer patients. Cancer Chemotherapy and Pharmacology. 84(5). 977–986. 4 indexed citations

Agarwal, Suresh, Sathej Gopalakrishnan, Sven Mensing, et al.. (2019). Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure‐response analysis. Hematological Oncology. 37(4). 464–473. 29 indexed citations

Gopalakrishnan, Sathej, Sven Mensing, Rajeev Menon, & Jiuhong Zha. (2018). Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Hepatitis C Virus-Infected Cirrhotic and Non-cirrhotic Patients: Analyses Across Nine Phase III Studies. Clinical Pharmacokinetics. 57(11). 1407–1419. 1 indexed citations

10.

Gopalakrishnan, Sathej, Brenda Chyla, Sven Mensing, et al.. (2017). Sustained Minimal Residual Disease Negativity Predicted in Chronic Lymphocytic Leukemia Patients Treated with Venetoclax Combination Therapy for 2 Years: an Integrated Mechanistic Analysis of Multiple Phase I and II Studies. Blood. 130. 4318–4318. 2 indexed citations

11.

Polepally, Akshanth R., Haoyu Wang, Patrick Marroum, et al.. (2017). Application of Exposure-Response Analyses to Establish the Pharmacodynamic Similarity of a Once-Daily Regimen to an Approved Twice-Daily Dosing Regimen for the Treatment of HCV Infection. The AAPS Journal. 19(5). 1523–1535. 1 indexed citations

12.

Polepally, Akshanth R., Sven Mensing, Amit Khatri, et al.. (2016). Dose- and Formulation-Dependent Non-Linear Pharmacokinetic Model of Paritaprevir, a Protease Inhibitor for the Treatment of Hepatitis C Virus Infection: Combined Analysis from 12 Phase I Studies. Clinical Pharmacokinetics. 55(9). 1091–1101. 3 indexed citations

13.

Freise, Kevin J., Sven Mensing, Shekman Wong, et al.. (2016). Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. Clinical Pharmacokinetics. 56(5). 515–523. 52 indexed citations

14.

Gopalakrishnan, Sathej, Amit Khatri, Sven Mensing, et al.. (2016). Exposure–Response Relationship for Ombitasvir and Paritaprevir/Ritonavir in Hepatitis C Virus Subgenotype 1b-Infected Japanese Patients in the Phase 3 Randomized GIFT-I Study. Advances in Therapy. 33(4). 670–683. 3 indexed citations

15.

Khatri, Amit, Sven Mensing, Thomas Podsadecki, et al.. (2016). Exposure-Efficacy Analyses of Ombitasvir, Paritaprevir/Ritonavir with Dasabuvir ± Ribavirin in HCV Genotype 1-Infected Patients. Clinical Drug Investigation. 36(8). 625–635. 3 indexed citations

16.

Gopalakrishnan, Sathej, Akshanth R. Polepally, Sven Mensing, Amit Khatri, & Rajeev Menon. (2016). Population Pharmacokinetics of Paritaprevir, Ombitasvir, and Ritonavir in Japanese Patients with Hepatitis C Virus Genotype 1b Infection. Clinical Pharmacokinetics. 56(1). 1–10. 15 indexed citations

17.

Polepally, Akshanth R., et al.. (2016). Effects of Mild and Moderate Renal Impairment on Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir, and Ribavirin Pharmacokinetics in Patients with Chronic HCV Infection. European Journal of Drug Metabolism and Pharmacokinetics. 42(2). 333–339. 14 indexed citations

18.

Mensing, Sven, Akshanth R. Polepally, Amit Khatri, et al.. (2015). Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Patients with Hepatitis C Virus Genotype 1 Infection: Combined Analysis from 9 Phase 1b/2 Studies. The AAPS Journal. 18(1). 270–280. 11 indexed citations

19.

Sharma, Shringi, Jeffrey S. Hyams, Sven Mensing, et al.. (2015). Pharmacokinetics and Exposure–Efficacy Relationship of Adalimumab in Pediatric Patients with Moderate to Severe Crohnʼs Disease. Inflammatory Bowel Diseases. 21(4). 783–792. 82 indexed citations

20.

Yang, Jianning, Peter Noertersheuser, Sven Mensing, et al.. (2014). Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia. Cancer Chemotherapy and Pharmacology. 74(3). 593–602. 118 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact